(Reuters) -Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate, sending shares in Denmark's first so-called meme stock tumbling 75% in ...
Shares in Orphazyme A/S soared after trading started in the U.S., indicating that interest in Denmark’s first meme stock is alive and well despite the biotech firm’s failure to win regulatory approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results